Skip to content

Author

H. Yassine

We have 6 of 229 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Sep 2026

Seroprevalence of HSV-1 and HSV-2 in the urban population of Qatar: a population-based study.

OBJECTIVES Epidemiological data on herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) infections remain limited in the Middle East and North Africa. This study estimated HSV-1 and HSV-2 seroprevalence in the urban population of Qatar and examined associations with demographic characteristics. METHODS A retrospect...

Gheyath K Nasrallah, F. Issa, P. Nizamuddin et al. · 0 citations
Open access Sep 2026

Two Versus One COVID-19 Vaccine Dose After Prior SARS-CoV-2 Infection: A Nationwide Retrospective Cohort Study

Abstract Background Immune protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) varies by prior infection and vaccination history. This study evaluated whether 2 coronavirus disease (COVID-19) vaccine doses after prior infection provide additional protection compared with a single dose. Metho...

H. Chemaitelly, H. Ayoub, Peter V. Coyle et al. · 0 citations
Open access Aug 2026

Evaluating COVID-19 vaccine effectiveness across epidemiologic designs: test-negative case-control versus retrospective cohort analyses in a nationwide study

Abstract Background Observational studies are central to assessing vaccine effectiveness and informing public health policy. The two most common designs are test-negative case-control and cohort studies, yet direct comparisons of their performance using the same population, data sources, and analytic strategies remain...

Layan Sukik, Pradipta Paul, H. Ayoub et al. · 0 citations
Open access Sep 2026

Mechanistic inhibition of herpes simplex virus-1 UL21 immune-evasion function by natural-product scaffolds: A multi-tier docking, dynamics, and energetic profiling approach

These findings identify natural-product scaffolds with high potential to modulate UL21-mediated immune suppression, with kaempferol 3,7,4′-tri-O-β-glucoside emerging as the most promising candidate and provide a foundation for experimental validation and future antiviral drug development targeting HSV-1.

Muhammad Suleman, Imtiaz Ali, A. M. Sayaf et al. · 0 citations
Open access Jul 2026

Healthy vaccinee effect did not bias COVID-19 vaccine effectiveness estimates

It is shown that vaccine effectiveness against infection and severe, critical, or fatal COVID-19 remained consistent across matching strategies, despite differences in non-COVID-19 mortality, highlighting the importance of using specific outcomes in vaccine effectiveness studies.

H. Chemaitelly, H. Ayoub, Peter V. Coyle et al. · 0 citations
Open access Aug 2026

Genetic Determinants of Infectious Diseases in the Qatari Population

The distribution of infection-related host genetic variants in Qatar is explored and substantial differences in pathogen-associated host variants in a diverse Qatari cohort are revealed, highlighting the need for follow-up validation and future GWAS discovery efforts.

M. Smatti, Y. Al-Sarraj, O. Albagha et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.